Defence Therapeutics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DTCFF research report →
Companydefencetherapeutics.com
Defence Therapeutics Inc. , a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells.
- CEO
- Sebastien Plouffe
- IPO
- 2021
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $20.30M
- P/E
- -5.75
- P/S
- 0.00
- P/B
- -20.35
- EV/EBITDA
- -6.63
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 422.19%
- ROIC
- -1574.06%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-4,000,000 · 69.68%
- EPS
- $0.00 · 100.00%
- Op Income
- $-3,000,000
- FCF YoY
- 33.21%
Performance & Tape
- 52W High
- $0.78
- 52W Low
- $0.31
- 50D MA
- $0.40
- 200D MA
- $0.49
- Beta
- 1.39
- Avg Volume
- 3.68K
Get TickerSpark's AI analysis on DTCFF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our DTCFF Coverage
We haven't published any research on DTCFF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DTCFF Report →